News • Multiple myeloma therapy

Finding a formula for blood cancer vaccine

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December.

This is the first study to experimentally determine which byproducts from the mutation of tumors (known as neoantigens) have the ability to provoke the immune system into recognizing and killing cancer cells in multiple myeloma patients. The results provide the foundation for using neoantigen-targeting strategies such as cancer vaccines in future trials for multiple myeloma patients. Multiple myeloma is a malignancy of plasma cells affecting 30,000 people a year.

Photo
Illustration of multiple myeloma

© Scientific Animations Inc.

Next-generation sequencing data was analyzed to describe the landscape of neoantigens in 184 patients, and researchers identified neoantigen-specific immune cells triggered by immunotherapy. Additionally, they showed an increase in neoantigens in patients who had relapsed myeloma versus new patients, which may indicate potential for greater immune responses to immunotherapy in these patients. The study also identifies common neoantigens between patients, which could lead to new vaccine therapies.

“Tumor neoantigens represent excellent targets for immunotherapy, due to their specific expression in cancer tissue,” said Samir Parekh, MD, Associate Professor of Oncological Sciences and Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine. “Until now, there has been no direct evidence that DNA mutations induce neoantigen-specific T-cell responses following immunotherapy in multiple myeloma.”

Stemming from this research, co-author Nina Bhardwaj, MD, PhD, Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine, and colleagues are pursuing a clinical trial investigating the safety and responsiveness of a personalized neoantigen vaccine for the treatment of cancers including multiple myeloma.


Source: Mount Sinai Health System

20.12.2019

Read all latest stories

Related articles

Photo

News • Blood cancer research

Covid-19 booster vaccine strengthens immunity in lymphoma patients

Research by the University of Southampton has shown that repeated Covid-19 vaccination increases the ability of lymphoma patients to prevent infection from the virus, particularly after four doses.

Photo

News • Good killer cells

Cellular immunotherapy: a new approach against cancer

Chemotherapy, radiotherapy or surgery – these are the three common forms of cancer therapy. Now, lymphoma specialists in Essen are investigating the possibility of a different approach.

Photo

News • Radiation and immunotherapy

Promising combination therapy against "cold" breast cancer tumors

US researchers have discovered that radiation therapy combined with two types of immunotherapy can control tumors in preclinical models of triple negative breast cancer.

Related products

Beckman Coulter · Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter · Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Beckman Coulter · DxH 500 Series

Blood Cell Counter

· Beckman Coulter · DxH 500 Series

Beckman Coulter Diagnostics
Beckman Coulter · DxH 690T

Blood Cell Counter

Beckman Coulter · DxH 690T

Beckman Coulter Diagnostics
Beckman Coulter · DxH 900 Hematology Analyzer

Integrated Hematology

Beckman Coulter · DxH 900 Hematology Analyzer

Beckman Coulter Diagnostics
Beckman Coulter · Early Sepsis Indicator

Blood Cell Counter

Beckman Coulter · Early Sepsis Indicator

Beckman Coulter Diagnostics
Subscribe to Newsletter